Mounjaro®
Starting from £179.99/mo
Start journey Learn moreA rash after starting Mounjaro (tirzepatide) is one of the more common things people search images for — and it makes sense to want a visual reference before calling your prescriber. Skin reactions linked to Mounjaro range from mild redness and swelling at the injection site to broader rashes that spread away from where the pen was used. Most are localised and settle within a few days; a small number signal something that needs prompt medical attention. This page describes what each type looks like, what the clinical evidence says, and which signs mean you should stop waiting and get help. Because Mounjaro is a prescription-only medicine, any persistent or worsening skin reaction should be discussed with the prescriber who issued your treatment.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The images most commonly shared online show a circular patch of redness (typically 1–5 cm across) centred exactly on the injection point. The skin may look slightly raised and feel warm or itchy to the touch. Some people describe a small firm bump under the skin, like a shallow bruise that never quite surfaced; others see a flat pink flush that fades within 24 hours. Occasionally there is minor swelling or a pale halo around the red area.
These localised reactions are well-documented. The NHS tirzepatide medicines page lists injection-site redness and swelling among the common side effects of Mounjaro. They tend to appear within minutes to a couple of hours of the injection and usually resolve without treatment. Rotating injection sites (abdomen, thigh, upper arm) across consecutive weekly doses reduces the chance of the same patch of skin becoming repeatedly irritated. If the area remains red, hot or painful beyond 48 hours, or if you notice hard nodules forming under the skin over time, let your prescriber know.
One practical point: if you are looking at pictures circulating on social media or forums, keep in mind that lighting and skin tone affect how a reaction photographs. A reaction that looks dramatic on a fair-skinned arm may present as a subtle darker patch on deeper skin tones. Photographs are useful context, not a substitute for clinical assessment. If you prefer to research the medication without browsing clinical photography, our Mounjaro without pictures page covers the treatment in detail using text and diagrams alone. For a broader look at how Mounjaro appears in clinical and patient photography, our Mounjaro visual reference page covers the pen and the device in more detail.
A generalised rash does not stay put. Instead of a circle around the injection point, it spreads to areas of skin the pen never touched, the torso, arms, neck or face. The most frequently reported pattern is urticaria, commonly called hives: raised, pale or pink welts on a red base that tend to migrate across the skin and itch intensely. Individual welts can merge into larger plaques. Some people report a flatter, blotchy redness rather than the classic raised welt pattern.
This type of reaction is less common than site-localised redness but more clinically significant. It suggests the immune system is responding to tirzepatide itself rather than to the mechanical trauma of the needle or the excipients in the formulation at that specific spot. You should contact your prescriber the same day if a generalised rash appears, do not wait for your next scheduled check-in. They may recommend antihistamines, advise pausing treatment, or arrange a face-to-face review depending on the pattern and your history. For a detailed breakdown of skin-rash patterns and what drives each one, the Mounjaro rash guide covers the mechanism and management in full.
Pictures help, but the distribution of the rash matters as much as its appearance: a rash confined to one body area behaves differently from one that is spreading rapidly across multiple areas. If it is moving fast, treat that as urgent.
Anaphylaxis is rare with Mounjaro but it is a known risk with any injectable medicine, and the visual signs are distinct. Look for swelling of the lips, tongue or throat, you may see the lips thickening or the face becoming puffy around the eyes and cheeks within minutes of the injection. The skin may show a rapid-spreading red flush or widespread hives across the chest and neck simultaneously. The critical difference from a standard generalised rash is that these skin changes appear alongside other symptoms: throat tightness, difficulty swallowing or breathing, a racing or irregular heartbeat, dizziness, or a sudden drop in blood pressure causing the person to feel faint.
This combination is an emergency. Call 999 immediately. Do not take an antihistamine and observe, anaphylaxis can deteriorate very quickly. If you carry an adrenaline auto-injector for another known allergy, use it. Anyone who has experienced an anaphylactic reaction to Mounjaro should not take another dose until they have been assessed by an appropriate specialist.
The MHRA Yellow Card scheme exists precisely to capture serious reactions like this: submitting a report after receiving emergency care helps regulators and manufacturers track rare events in the real-world population, something clinical trials, however large, cannot fully replicate. You can also read more about the full side-effect picture at our Mounjaro skin rash page, which includes guidance on when symptoms need a prescriber call versus when they can be monitored at home.
The first week of treatment is when injection-site reactions are most likely to appear, partly because your skin has not yet adapted to the weekly subcutaneous injection and partly because any immune sensitivity tends to declare itself early. If a mild, localised reaction appears after your first or second dose, document it with a photograph under good light, note when it started relative to the injection, how large it is, and whether it is changing. That record is genuinely useful if you do end up speaking to your prescriber.
At nume, your Mounjaro arrives from our GPhC-registered pharmacy in plain, unbranded packaging via DPD with live tracking, and a named prescriber, not software, reviewed your consultation before it was dispatched. If a skin reaction gives you pause, our aftercare team is available seven days a week; reaching us through the contact page is the quickest route. For context on the broader experience of starting tirzepatide, the tirzepatide overview covers what to expect week by week. And if you are still weighing up whether treatment is right for you, the cost and what's included page sets out exactly what the treatment price covers before any clinical decision is made.
Skin reactions are not a reason to assume treatment will not suit you, but they are a reason to keep your prescriber informed. That's the point of same-day clinical access.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.